| Literature DB >> 26614753 |
Abstract
Although the amyloid-β protein associated with the Alzheimer's disease plaque has been detectable in living people for over a decade, its importance in the pathogenesis of Alzheimer's disease is still debated. The frequent presence of amyloid-β in the brains of cognitively healthy older people has been interpreted as evidence against a causative role. If amyloid-β is crucial to the development of Alzheimer's disease, it should be associated with other Alzheimer's disease-like neurological changes. This review examines whether amyloid-β is associated with other biomarkers indicative of early Alzheimer's disease in normal older people. The preponderance of evidence links amyloid-β to functional change, progressive brain atrophy, and cognitive decline. Individuals at greatest risk of decline seem to be those with evidence of both amyloid-β and findings suggestive of neurodegeneration. The crucial question is thus how amyloid-β is related to brain degeneration and how these two processes interact to cause cognitive decline and dementia.Entities:
Keywords: Alzheimer’s disease; ageing; amyloid; biomarkers; neurodegeneration
Mesh:
Substances:
Year: 2015 PMID: 26614753 PMCID: PMC4990654 DOI: 10.1093/brain/awv326
Source DB: PubMed Journal: Brain ISSN: 0006-8950 Impact factor: 13.501